WASHINGTON — The Trump administration is ready to defend its sweeping new drug pricing proposals. In a new Q&A, obtained by STAT, its authors parry several key criticisms — some already aired, some expected — from drug makers and other groups.

The document, which is expected to be published later Tuesday according to a senior administration official, represents a quick response from the administration, which only unveiled the policy in an address on Thursday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy